Funding Round Brings in Successful bid for Southern Company

The Scottish Biotech company Ryboquin has acquired Nanogenic Solutions, to form a new product and platform company, which, following acquisition will be named Nanogenics Limited. Ryboquin raised £4.45 million in its third funding round from new and existing share-holders to acquire the West Sussex-based business.

The combined company will be focused on developing safe, efficacious and regular dosing of all forms of gene therapy.

Currently viruses and liposomes are used in this process, which have limited applications, severe side-effects and expensive technical problems. Nanogenics is developing LipTide, an artificial virus, which acts as a custom-built delivery system that can be modified to target different cell types and deliver different payloads, making the promise of gene therapy one step closer to reality.